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OBJECTIVES: The purpose of this study is (1) to build
a pharmacoeconomic model to appropriately represent
the outcomes of a single dose almotriptan treatment 
in migraine patients, and (2) to assess the cost-beneﬁt of
almotriptan compared to placebo based on clinical trial
results.
METHODS: Cost-beneﬁt analyses from a societal 
perspective are performed. Time horizon of the model is
deﬁned as a single migraine episode, lasting one workday.
The probabilities of individual events are based on 
clinical trial data published by Pascual et al (2000).
Healthcare consumption probabilities, the likelihood of a
physician or ER (emergency room) visits were drawn
from Adelman et al (1996). Health care cost data are
drawn from Hu et al (1999), who studied speciﬁcally 
the migraineurs’ health care costs. Almotriptan cost is
assumed to be equal to that of sumatriptan because
almotriptan was not yet marketed in the USA at the time
the analysis was performed. In order to evaluate the
beneﬁt from treatment, productivity gain/loss was 
converted to monetary terms using the average market
wage in the United States. Average wage data are drawn
from the Statistical Abstract of the United States, 1999.
All health utilization costs and average daily wage were
converted to year 2000 dollars using consumer price
index (3%). The outcome measure for the cost-beneﬁt
model is net-beneﬁt.
RESULTS: Based on the model used in this study,
almotriptan is more cost-beneﬁcial than placebo, the 
difference of net-beneﬁt being $10.62. Breakeven point is
reached at the price of $26.62 for almotriptan. Placebo
will become more beneﬁcial than almotriptan when
almotriptan cost $26.52 and above.
CONCLUSIONS: Even though a relatively large placebo
effect is observed in migraine treatment, when almo-
triptan price is $26.62 and below, almotriptan is the 
preferred choice of treatment to society over placebo
treatment considering net-beneﬁt.
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OBJECTIVES: To investigate the prescribing patterns of
fentanyl transdermal system and oxycodone HCL con-
trolled-release for chronic nonmalignant pain indications
in the Veterans Administration System. A secondary
objective was to estimate the incremental cost savings if
transdermal fentanyl were used more frequently.
METHODS: A retrospective analysis of the prescription,
inpatient and outpatient treatment ﬁles of the VISN-10
(Ohio) VA database from June 1996 to June 2001 was
conducted. Subjects were included if they received at least
90-days supply of medication and excluded if they were
treated for a malignancy. Potential cost impact was 
estimated by converting all oxycodone HCL controlled-
release prescriptions to transdermal fentanyl, based on
the recommended initial dosing conversion, and calculat-
ing the difference in cost between the two scenarios.
RESULTS: 1,917 transdermal fentanyl and 1,301 
oxycodone HCL controlled-release prescriptions were
written during the study period. Transdermal fentanyl
users were slightly older (59 vs. 52 years) and had a
similar chronic disease index score (6.9 vs. 6.6). The
average dose of transdermal fentanyl was 54mcg/hr 
and oxycodone HCL controlled-release was 66mg/day.
Transdermal fentanyl patients received an average of 
one patch every 2.9 days (manufacturer recommends one
patch every 3 days). Oxycodone HCL controlled-release
patients received an average of 3.3 doses per day (manu-
facturer recommends two doses daily). Using transdermal
fentanyl in place of oxycodone HCL controlled-release
could potentially result in a cost savings of $43,900 over
the study period, or $1.20 per patient per day of therapy.
CONCLUSION: The dosing frequency of transdermal
fentanyl was observed to be consistent with prescribing
information (ie, one patch every 2.9 days, or a 4% excess
above the PI), whereas the dosing frequency of oxycodone
HCL controlled-release exceeded the PI by 65% (ie, 3.3
doses per day). Using transdermal fentanyl instead of 
oxycodone HCL controlled-release has potential to
reduce pharmacy costs.
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OBJECTIVES: The study tests the hypothesis that 
physicians and patients value “quality-of-life” beneﬁts
more highly than managed care decision makers. In con-
ducting this test, we focus on the treatment of migraine
headaches, a therapeutic area for which current drugs
exhibit a wide range of costs and beneﬁts.
METHODS: To test the hypothesis, we conducted
surveys and conjoint exercises with physicians (N = 10),
patients (N = 26) and MCO formulary managers (N = 5).
Conjoint analysis is a survey-based technique for objec-
tively measuring willingness to trade off different product
(or service) attributes.
RESULTS: We found that both patients and their physi-
cians are willing to spend four to ﬁve times more than
